EGFR and non-small cell lung carcinoma: Clinical trials on gefitinib efficacy for advanced NSCLC with EGFR mutations in Japan were summarized by Morita et al. [9] A total of 148 NSCLC patients with EGFR mutations from seven eligible trials were identified.